Cytomegalovirus infection in living-donor and cadaveric lung transplantations†
Open Access
- 7 August 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 25 (5) , 710-715
Abstract
Cytomegalovirus (CMV) infection remains a major cause of morbidity after lung transplantation. Some studies have reported prognostic factors for the postoperative development of CMV infection in cadaveric lung transplantation (CLT), but no research has been performed in living-donor lobar lung transplantation (LDLLT). Therefore, we analysed the possible risk factors of post-transplant CMV infection and the differences between LDLLT and CLT. The development of CMV disease and viraemia in 110 patients undergoing lung transplantation at Kyoto University Hospital in 2008–2015 were retrospectively assessed. The prognostic factors in the development of CMV infection and the differences between LDLLT and CLT were analysed. Among 110 patients, 58 LDLLTs and 52 CLTs were performed. The 3-year freedom rates from CMV disease and viraemia were 92.0% and 58.5%, respectively. There was no difference in the development of CMV infection between LDLLT and CLT (disease: 94.6% vs 91.0%, P = 0.58 and viraemia: 59.3% vs 57.2%, P = 0.76). In preoperative anti-CMV immunoglobulin status, R−D+ recipients (recipient: negative, donor: positive) and R–D– recipients (recipient: negative, donor: negative) tended to have higher and lower cumulative incidences, respectively, of CMV infection (disease: P = 0.34 and viraemia: P = 0.24) than that with R+ recipients (recipient: seropositive). Significantly lower cumulative incidence of CMV viraemia was observed in patients receiving 12-month prophylactic medication (70.6% vs 36.8%, P < 0.001). Twenty-eight patients (25.5%) had early cessation of anti-CMV prophylaxis due to toxicity; however, the extended prophylaxis duration did not increase the incidence of early cessation (P = 0.88). These trends were seen in both LDLLT and CLT. We found that there was no difference in the development of CMV infection between LDLLT and CLT. Twelve-month prophylaxis protocol provides beneficial effect without increased toxicity also in LDLLT.Keywords
This publication has 20 references indexed in Scilit:
- Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patients†European Journal of Cardio-Thoracic Surgery, 2014
- Registry of the Japanese Society of Lung and Heart–Lung Transplantation: official Japanese lung transplantation report, 2014General Thoracic and Cardiovascular Surgery, 2014
- International Survey of Cytomegalovirus Management in Solid Organ Transplantation After the Publication of Consensus GuidelinesTransplantation, 2013
- Cytomegalovirus Infections in Solid Organ Transplantation: A ReviewInfection & Chemotherapy, 2013
- Cytomegalovirus Prevention in High-risk Lung Transplant Recipients: Comparison of 3- vs 12-Month Valganciclovir TherapyThe Journal of Heart and Lung Transplantation, 2009
- Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2007
- Living-donor lobar lung transplantation for various lung diseasesThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant RecipientsJournal of Clinical Microbiology, 2002
- Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2000
- Rapid Diagnosis of Cytomegalovirus Infections by Direct Immunoperoxidase Staining with Human Monoclonal Antibody against an Immediate‐Early AntigenMicrobiology and Immunology, 1991